TLL-018 (a JAK1/TYK2 agent) vs. Tofacitinib in RA
Dr. Peter Nash reporting on abstract LB0001 from EULAR 2023 in Milan, Italy.
Watch video →What's hot
View all perspectives
What's Hot
EULAR 2023 Day 4 Recap
Join Drs. Jack Cush, David Liew and Bella Mehta as they recap data presented on Day 4 at EULAR 2023 in Milan, Italy.
Watch video →
Upadacitinib in SLE
Dr. Peter Nash reports on abstract OP0139 EULAR 2023 in Milan, Italy.
Watch video →
Daily Recap: Day Three EULAR 2023
Drs. Antoni Chan, Jack Cush and Yuz Yusof report from EULAR 2023 in Milan, Italy.
Watch video →
Concomitant Methotrexate Therapy in Psoriatic Arthritis
Dr. Eric Ruderman discusses abstract OP0063 presented at EULAR 2023 in Milan, Italy.
Watch video →
Update on CAR T-Cell Therapy in SLE & Autoimmune Diseases
Dr. Peter Nash reporting from EULAR 2023 in Milan, Italy.
Watch video →
JAKpot or JAKnot
Dr. Jack Cush, executive editor of RheumNow, reporting on abstract OP0219 from EULAR 2023 in Milan, Italy.
Watch video →
Should you Assess Rheumatoid Factor Serially?
Dr. Jack Cush discusses abstract OP0272 at EULAR 2023 in Milan, Italy.
Watch video →
APIPPRA Study in Preclinical RA
Dr. Jack Cush, executive editor, RheumNow, discussing OP0130 from EULAR 2023 in Milan, Italy.
Watch video →
The Importance of Identifying Central Pain in PsA
Dr. Eric Ruderman discusses abstracts OP0068 and OP0299 at EULAR 2023 in Milan, Italy.
Watch video →
ARD & RMD Open ARD_BMJ
2 years 4 months ago
EULAR/PRES recos for sJIA & AOSD
🔹sJIA = AOSD l
👉 Unique name: Still’s disease
🔹Start IL1i or IL6i as soon as diagnosis made
🔹MAS ⚠️
🔹Emerging issue: lung disease
👉Screening (HRCT if suspicion)
#EULAR2023
Pr B Fautrel & F deBenedetti
Key slides 👇🏼
NZ https://t.co/x1Snf8WI99
Day 4 was a half day closeout to the EULAR 2023 Congress. For me the big presentations were the late breaking abstracts, although there were other review and abstract sessions for those remaining. Many people missed the last day (June 3rd) of the meeting as a pending Milan airport strike on June 4th dictated last-minute changes to travel and learning. Here are a few of my favorite abstracts from the Late Breaker Session.
Janet Pope Janetbirdope
2 years 4 months ago
#Top #EULAR learnings #SLE #recommendations 1 Limit #prednisone 2 use #biologics early if poor prognosis 3 #lupus #nephritis - treat early with #belimumab or #voclosporin and more Rx in #RCTs #gamechanger https://t.co/JHQHu91tud
Dr. John Cush RheumNow
2 years 4 months ago
AOSD: Young vs. Elderly Onset AOSDis an autoinflammatory condition characterized by fevers, arthritis, and rash. It is considered an orphan disease because of its low prevalence - it is reported anywhere between 16 to 40 per ten million. https://t.co/bB2mpul3j7 https://t.co/ic6mY04ddF
Dr. John Cush RheumNow
2 years 4 months ago
Promising new therapies in SLE
Dr. Yuz Yusof ( @Yuz6Yusof ) weighs in.
The pharmacology treatment in SLE is a rapidly expanding field of research that provides excitement and optimism to both the patients and the clinicians.
https://t.co/cdVw771HDs https://t.co/OYcN8hFLcP
Dr. John Cush RheumNow
2 years 4 months ago
An update on JAK inhibitors and cardiovascular risks
Dr. Antoni Chan ( @synovialjoints ) shares #EULAR23 developments on JAK/TYK2 inhibitors.
https://t.co/VovWE2OuXW https://t.co/QXKZLh5RuK
Some subjects in rheumatology seem to create contention the more they get explored, and one of those areas is a traditional crowd favourite for discussion at EULAR - clinically suspect arthralgias. At EULAR 2023 in Milan, the perfect platform was provided for an airing of grievances, in a debate entitled ‘Clinically suspect arthralgias: fact or myth’.
Dr. John Cush RheumNow
2 years 4 months ago
Targeted therapies in Sjogren’s syndrome: are we close?
There is a clear unmet need for new and effective therapies in primary Sjogren’s Syndrome (pSS) patients, as there is no current licensed therapies.
https://t.co/B4kKDjhuh7 https://t.co/pGWpSNhJe2
Poster Hall